CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance

Despite wide use of anti-vascular endothelial growth factor (VEGF) therapy for many solid cancers, most individuals become resistant to this therapy, leading to disease progression. Therefore, new biomarkers and strategies for blocking adaptive resistance of cancer to anti-VEGF therapy are needed. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shaolin, Mangala, Lingegowda S., Hu, Wen, Bayaktar, Emine, Yokoi, Akira, Hu, Wei, Pradeep, Sunila, Lee, Sanghoon, Piehowski, Paul D., Villar-Prados, Alejandro, Wu, Sherry Y., McGuire, Michael H., Lara, Olivia D., Rodriguez-Aguayo, Cristian, LaFargue, Christopher J., Jennings, Nicholas B., Rodland, Karin D., Liu, Tao, Kundra, Vikas, Ram, Prahlad T., Ramakrishnan, Sundaram, Lopez-Berestein, Gabriel, Coleman, Robert L., Sood, Anil K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422976/
https://www.ncbi.nlm.nih.gov/pubmed/34407412
http://dx.doi.org/10.1016/j.celrep.2021.109549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422976/
https://www.ncbi.nlm.nih.gov/pubmed/34407412
http://dx.doi.org/10.1016/j.celrep.2021.109549

Ejemplares similares